Sudeep Pharma Q2FY27 results: EBITDA rises 32% YoY to ₹73.2 crore
NiveshIQ
NSE: SUDEEPPHRM · Chemicals
Sudeep Pharma Ltd.
₹1,107.20▲ ₹38.90 (+3.64%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUDEEPPHRM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sudeep Pharma Ltd.
Sudeep Pharma Limited, headquartered in Vadodara, specializes in manufacturing excipients and specialty ingredients for pharmaceutical, food, and nutrition sectors across India, the US, and globally. The product portfolio includes mineral salts such as iron, calcium, zinc, and magnesium, as well as micronutrient premixes, liposomal and encapsulated ingredients, and spray-dried formats used in sports nutrition, medical nutrition, infant nutrition, fortified staples, and functional foods. In Q2 FY27, the company reported a 32% year-over-year rise in EBITDA to ₹73.2 crore and a 20.9% revenue increase to ₹706 crore, driven by strong demand for its nutraceutical and beverage ingredients. Recent developments include FDA approval for a new Nandesari manufacturing facility and expansion into batte
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹454.67 Cr +6.70% | ₹497.41 Cr +9.40% | ₹642.26 Cr +29.10% |
| EBITDA Margin | 41.11% | 39.82% | 34.55% |
| Net Profit | ₹133.19 Cr +113.70% | ₹138.69 Cr +4.10% | ₹172.89 Cr +25.70% |
| EPS | ₹11.79 | ₹12.28 | ₹15.50 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Sudeep Pharma Limited (SUDEEPPHRM.NS) Seasonal Returns Chart - Yahoo Finance
Hold Sudeep Pharma: target of Rs 1100: ICICI Securities
🔒
+ 3 more stories about Sudeep Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹197 Cr, PAT ₹52 Cr, EPS ₹4.59, EBITDA margin 37.2%. Growth context: revenue YoY +20.9%, PAT YoY +13.3%, revenue QoQ +24.3%, PAT QoQ +27.8%. Street verdict: beat, revenue surprise +10.4%, PAT surprise +9.2%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new capacity addition ...
FY26 (last completed FY): revenue ₹642 Cr, PAT ₹173 Cr, EBITDA margin 34.6%, EPS ₹15.50. Year-on-year: revenue YoY +29.1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Chemicals stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUDEEPPHRM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUDEEPPHRM alongside your other holdings
Unlock full SUDEEPPHRM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sudeep Pharma Ltd.?
NiveshIQ detects active intelligence signals for Sudeep Pharma Ltd. (SUDEEPPHRM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sudeep Pharma Ltd.?
Sudeep Pharma Ltd. operates in the Chemicals sector with a market capitalisation of ₹745,460.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.